Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
about
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectivesThe Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes MellitusThe efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjectsβ cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East AsiansSitagliptin: Is It Effective in Routine Clinical Practice?Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes.Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.
P2860
Q26749165-7616EA6E-4DD7-493A-AFE8-A7BD569ABCC2Q33619167-7F81E17E-0BAA-4012-B5C0-A13857EC7DB0Q33775600-02ED3234-22FB-41C6-B7DF-DB0E77AABF48Q35166849-48F90679-4BAB-44C3-8628-66D938C2987EQ35572729-3E586106-F845-4DAA-B41D-009EB5046F28Q35671855-AB2AE910-D411-4C4D-A60C-1FEA591A6B24Q35681641-746EA8A3-E520-437B-AF34-1998EF1DB079Q35754150-C8C63FD3-63A1-4F29-90E8-89C0DDE397CEQ35910737-F75FC660-C380-4314-9D82-33B27114FC28Q36429742-C4105078-DEFB-4DEF-BA3F-5CCAAFCC4C11Q36856980-166020C6-18D8-4925-9912-94203BC6603FQ37008619-E2306E0F-CE1F-4D9D-84BF-59E519B6EA5DQ47148933-07F15E76-9FA6-4BB1-9D8A-33B03C969821Q47367938-A1357053-1E25-40D0-8437-7BF644202AF1Q50050575-7D4383E5-4B39-4DD9-9EA6-F1BBB6D24A98
P2860
Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Factors associated with reduce ...... eated for 1.5 years or longer.
@en
type
label
Factors associated with reduce ...... eated for 1.5 years or longer.
@en
prefLabel
Factors associated with reduce ...... eated for 1.5 years or longer.
@en
P2860
P356
P1476
Factors associated with reduce ...... eated for 1.5 years or longer.
@en
P2093
Akira Kanamori
Ikuro Matsuba
P2860
P304
P356
10.4021/JOCMR1256W
P577
2013-04-23T00:00:00Z